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http://dx.doi.org/10.1016/j.jmii.2012Infections caused by Candida dubliniensis in humans are rare and have never been reported in
Taiwan. We report two cancer patients with catheter-related fungemia due to C. dubliniensis
infection in Taiwan. The two isolates were confirmed to the species level using an oligonucle-
otide array system and sequence analysis, and both showed high in vitro susceptibilities to nine
antifungal agents. The catheters were removed, and both patients responded well to anti-
fungal treatment. Although this type of infection is rare, physicians should consider C. dubli-
niensis as one of the possible pathogens causing catheter-related infections in Taiwan.
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reserved.Introduction
Candida species are important causative agents of
healthcare-associated infections, especially in criticallyent of Internal Medicine,
National Taiwan University,
tw (P.-R. Hsueh).
an Society of Microbiology. Publ
.10.001ill patients with intravascular catheters, those on broad-
spectrum antibiotics, those on mechanical ventilation,
and those on immunosuppressive agents and parenteral
nutrition.1 Candida albicans remains the predominant
cause of invasive candidiasis and accounts for more than
50% of all cases; however, the incidence of invasive
candidiasis due to non-albicans Candida species such
as C. tropicalis, C. glabrata, and C. parapsilosis is
increasing.2,3ished by Elsevier Taiwan LLC. All rights reserved.
Catheter-related fungemia due to C. dubliniensis 307Candida dubliniensis was first characterized by Sullivan
et al in 1995.4 Since then, however, very few cases of
candidiasis due to this rare pathogen have been reported.
C. dubliniensis shares many features with C. albicans and,
therefore, can be misidentified in routine laboratory
methods in clinical microbiology laboratory. Thus, the
incidence of infection due to this causative pathogen may
be underreported. In Taiwan, C. dubliniensis has only been
reported in association with oropharyngeal carriage in HIV-
infected patients.5 In this report, we describe two cancer
patients with catheter-related fungemia due to C. dublin-
iensis in Taiwan.
Case reports
Case 1
A 62-year-old woman with rheumatic heart disease status
after mitral valve replacement and thyroid papillary
carcinoma was admitted to the National Taiwan University
Hospital because of congestive heart failure and progres-
sive dyspnea. She was intubated for acute respiratory
failure and was placed on dialysis. Several episodes of
healthcare-associated infections developed during hospi-
talization for which she received piperacillinetazobactam,
ertapenem, and cefepime. One month later, a new onset of
fever occurred, and ceftazidime was prescribed after col-
lecting blood for culture. Five days later, blood cultures
(Becton Dickinson Microbiology Systems, Sparks, MD, USA)
from the central venous catheter (CVC) yielded C. dublin-
iensis. The CVC was removed, and intravenous amphoter-
icin B (50 mg/day) for 14 days was added to the regimen to
cover candidemia. Thereafter, there was no fever and
repeated blood culture did not yield Candida spp.
Case 2
A 71-year-old man had received three courses of gemicitabin
and cisplatin as treatment for bladder cancer. Two months
after the final treatment, the patient presented with
symptoms and signs of progressive bladder cancer. A radical
cystectomy was performed. Approximately 8 days after the
operation, the patient developed fever. Empirical therapy
with ceftazidime was initiated but the patient responded to
the therapy unsatisfactorily. Culture of peripheral blood and
blood from the CVC yielded C. dubliniensis. The CVC was
removed, and intravenous fluconazole (400 mg/day) was
administered for 14 days. His clinical condition gradually
improved, and the patient was discharged uneventfully after
completing the full course of antibiotics.
The two isolates of C. dubliniensis were identified to
the species level by conventional laboratory procedures
and the Vitek Yeast Biochemical Card identification
system (bioMe´rieux Vitek, Marcy l’Etoile, France) (bio-
number 6102544061305370, 99% probability). An oligonu-
cleotide array system targeting the internal transcribed
spacer 1 and 2 region of the rRNA genes and sequence
analysis of the amplified internal transcribed spacer
region using the BLAST program confirmed that the
isolates were indeed C. dubliniensis (GenBank accession
no. HQ457430.1, 99% identity).6 The MIC values of nineantifungal agents against the two C. dubliniensis isolates
were determined by a commercial system with the
broth microdilution method (Sensititre YeastOne, SYO;
Trek Diagnostic Systems, West Sussex, UK). The two
isolates were susceptible to fluconazole, voriconazole,
itraconazole, caspofungin, micafungin, anidulafungin, and
5-flucytosine (Table 1).7Discussion
C. dubliniensis can cause invasive infections, especially in
immunocompromised patients. This rare pathogen has been
reported to cause human infection in the United States,
Australia, Europe, and Argentina. The prevalence of
C. dubliniensis as the causative agent of candidiemia ranges
from 0.96% in Argentina to approximately 2% in the United
States and the United Kingdom.8e12 To the best of our
knowledge, these are the first two cases of fungemia due to
C. dubliniensis in Taiwan. Both cases occurred in the same
2500-bed medical center during the period 2009e2010.
In this study, both cases were classified as healthcare-
associated catheter-related bloodstream infections, and
one of the patients had cancer during the episode of
infection. In a study reported by Chen et al,13 the majority
of patients (19 of 22, 86%) with C. dubliniensis fungemia
had healthcare-associated infections, and 79% of them had
vascular access devices.
The clinical outcomes of patients with C. dubliniensis
fungemia have not been well defined because of the limited
number of cases. In one series of four patients with
C. dubliniensis fungemia, one patient died as a conse-
quence of this infection.11 In another study, the 30-day
crude mortality rate was 27.7% (5/18).13 In the present
study, both patients survived for 5 and 8 days, respectively,
without any antifungal therapy and had favorable responses
after antifungal treatment and removal of the catheters.
These findings might indicate the potential low virulence of
the organism. However, further large-scale studies are
needed to better understand the clinical manifestations
and prognosis of C. dubliniensis fungemia.
We tested the in vitro activity of nine antifungal agents
against the two C. dubliniensis isolates. The MICs of the
tested echinocandins were highest for capsofungin, and
the MICs of the tested azoles were in the order
voriconazole < itraconzaole < posaconazole < fluconazole.
The MIC values were in agreement with those reported
previously13 against 22 C. dubliniensis isolates. In that study,
the MIC90 values of the tested azoles were in the order
voriconazole (0.016 mg/mL) < itraconzaole Z posaconazole
(0.125 mg/mL) < fluconazole (1.0 mg/mL). Based on the
above-mentioned in vitro studies, azoles remain the drugs of
choice to treat C. dubliniensis infections.
In conclusion, C. dubliniensis is an emerging pathogen
that causes invasive infections, and it may play an impor-
tant role in the clinical setting of bloodstream infections.14
Healthcare-associated catheter-related bloodstream
infections due to this pathogen may respond well to
appropriate antifungal agent and catheter removal. The
in vitro studies showed there was no resistance to anti-
fungal agents but that azoles are effective against
C. dubliniensis.
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